China has accounted for a 27.7% share of the global clinical trials activity in 2022, registering an increase when compared with the last ten-year average of a 16.5% share, according to GlobalData.
Go deeper with GlobalData
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Non-industry sponsored trials outnumber industry sponsored trials in China
Industry sponsored trials held a 38.1% share of all the clinical trials in the China in 2022, when compared with the ten-year average of 38.1%. Non-industry sponsored trials accounted for a 61.9% share in 2022 as against the average of 61.9% in the last ten years.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Top therapy areas for industry sponsored clinical trials in China
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataOncology was the leading therapy area for industry sponsored clinical trials in the China in 2022 with a 35.2% share, as against a five-year average of 33.1% and a ten-year average of 34.4%.
Infectious Disease held a 12.2% share in 2022, over a five-year average of 14.3% and a ten-year average of 13.6%.
Central Nervous System held an 11.8% share in 2022, compared to a five-year average of 11.3% and a ten-year average of 10.0%. Cardiovascular held an 8.8% share in 2022, as against a five-year average of 12.8% and a ten-year average of 12.4%.
Metabolic Disorders held an 8.6% share, over a five-year average of 9.8% and a ten-year average of 9.8%.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Top therapy areas for non-industry sponsored clinical trials in China
Oncology was the leading therapy area for non-industry sponsored clinical trials in the China in 2022 with a 35.4% share, as against a five-year average of 35.9% and a ten-year average of 34.4%.
Central Nervous System held a 22.4% share in 2022, over a five-year average of 18.2% and a ten-year average of 17.0%.
Cardiovascular held a 9.1% share in 2022, compared to a five-year average of 10.7% and a ten-year average of 11.9%. Infectious Disease held an 8.7% share in 2022, as against a five-year average of 8.6% and a ten-year average of 8.8%.
Gastrointestinal held a 6.1% share, over a five-year average of 7.0% and a ten-year average of 7.5%.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Phase I trials lead industry sponsored clinical trials in China in 2022
Phase I trials held a 54.2% share of industry sponsored clinical trials in the China in 2022, over a five-year average of 56.3% and a ten-year average of 38.6%.
Phase II trials held a 24.1% share in 2022, as against a five-year average of 19.8% and a ten-year average of 21.2%. Phase III trials held a 13.5% share in 2022, compared to a five-year average of 13.7% and a ten-year average of 22.1%.
Phase IV trials held an 8.2% share in 2022, over a five-year average of 10.2% and a ten-year average of 18.2%.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Phase II trials lead non-industry sponsored clinical trials in China in 2022
Phase II trials held a 40.4% share of non-industry sponsored clinical trials in the China in 2022, over a five-year average of 43.4% and a ten-year average of 46.8%.
Phase I trials held a 28.5% share in 2022, as against a five-year average of 22.4% and a ten-year average of 15.4%. Phase IV trials held a 25.8% share, compared to a five-year average of 27.5% and a ten-year average of 28.1%.
Phase III held a 5.3% share in 2022, over a five-year average of 6.7% and a ten-year average of 9.7%.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Methodology:
The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.
